Public release date: 13-Nov-2012 [ | E-mail | Share ] <\/p>\n
Contact: Vicki Cohn vcohn@liebertpub.com<\/a> 914-740-2100 x2156 Mary Ann Liebert, Inc.\/Genetic Engineering News<\/p>\n New Rochelle, NY, November 12, 2012--Radiolabeled agents are powerful tools for targeting and killing cancer cells and may help improve outcomes and lengthen survival times of patients with advanced disease that has spread beyond the initial tumor site. Effective therapy for metastatic cancer requires a combination of treatments, and the benefits of adding radionuclide therapy are explored in three studies published in Journal of Clinical Investigation, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The articles are available free on the Journal of Clinical Investigation website. <\/p>\n \"The preliminary therapeutic results reported in these case studies using radionuclide multimodality approaches are encouraging,\" says Co-Editor-in-Chief Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham. \"The outcomes described in these small, single center studies must be confirmed in larger trials before they can be translated into widespread oncology practice.\" <\/p>\n J. Harvey Turner, MD, FRACP, The University of Western Australia, Fremantle, coauthored two of the case studies and, in the Perspective article \"Multimodality Radionuclide Therapy of Progressive Disseminated Lymphoma and Neuroendocrine Tumors as a Paradigm for Cancer Control,\" he states that the synergistic effects that can be achieved by combining chemotherapy and radionuclides \"has the potential to enhance efficacy and minimize toxicity.\" Although advanced forms of lymphoma and neuroendocrine tumors are usually incurable, multimodal treatment approaches may be able to stop or slow tumor progression, achieve durable remission, prolong patient survival, and improve their quality of life. <\/p>\n ### <\/p>\n Paul Kruger, Julian Cooney, and J. Harvey Turner report that more patients survived longer and were free of disease when a radioimmunotherapeutic agent was added to their treatment regimen in the article \"Iodine-131 Rituximab Radioimmunotherapy with BEAM Conditioning and Autologous Stem Cell Transplant Salvage Therapy for Relapsed\/Refractory Aggressive Non-Hodgkin Lymphoma.\" <\/p>\n Phillip Claringbold, Richard Price, and J. Harvey Turner added a lutetium-177 labeled peptide to the therapeutic regimen of a group of patients with advanced neuroendocrine cancer and described substantially improved tumor control rates with no significant side effects. They report their findings in \"Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors.\" <\/p>\n About the Journal <\/p>\n Journal of Clinical Investigation, published 10 times a year in print and online, is under the editorial leadership of Editors Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham, and Robert K. Oldham, MD, Lower Keys Cancer Center, Key West, FL. Journal of Clinical Investigation is the only journal with a specific focus on cancer biotherapy, including monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapy. The Journal includes extensive reporting on advancements in radioimmunotherapy and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. Topics include antibody drug conjugates, fusion toxins and immunotoxins, nanoparticle therapy, vascular therapy, and inhibitors of proliferation signaling pathways. <\/p>\n<\/p>\n Read the rest here: Public release date: 13-Nov-2012 [ | E-mail | Share ] Contact: Vicki Cohn vcohn@liebertpub.com<\/a> 914-740-2100 x2156 Mary Ann Liebert, Inc.\/Genetic Engineering News New Rochelle, NY, November 12, 2012--Radiolabeled agents are powerful tools for targeting and killing cancer cells and may help improve outcomes and lengthen survival times of patients with advanced disease that has spread beyond the initial tumor site. Effective therapy for metastatic cancer requires a combination of treatments, and the benefits of adding radionuclide therapy are explored in three studies published in Journal of Clinical Investigation, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers Continue reading
\nCan the addition of radiolabeled treatments improve outcomes in advanced metastatic disease?<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"